Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition
Published version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
The tumor suppressor gene ATRX is frequently mutated in a variety of tumors including gliomas and liver cancers, which are highly unresponsive to current therapies. Here, we performed a genome-wide synthetic lethal screen, using CRISPR-Cas9 genome editing, to identify potential therapeutic targets specific for ATRX -mutated cancers. In isogenic hepatocellular carcinoma (HCC) cell lines engineered for ATRX loss, we identified 58 genes, including the checkpoint kinase WEE1 , uniquely required for the cell growth of ATRX null cells. Treatment with the WEE1 inhibitor AZD1775 robustly inhibited the growth of several ATRX-deficient HCC cell lines in vitro , as well as xenografts in vivo . The increased sensitivity to the WEE1 inhibitor was caused by accumulated DNA damage-induced apoptosis. AZD1775 also selectively inhibited the proliferation of patient-derived primary cell lines from gliomas with naturally occurring ATRX mutations, indicating that the synthetic lethal relationship between WEE1 and ATRX could be exploited in a broader spectrum of human tumors. As WEE1 inhibitors have been investigated in several phase II clinical trials, our discovery provides the basis for an easily clinically testable therapeutic strategy specific for cancers deficient in ATRX . SIGNIFICANCE: ATRX -mutant cancer cells depend on WEE1, which provides a basis for therapeutically targeting WEE1 in ATRX -deficient cancers. See related commentary by Cole, p. 375 .
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been used to identify genes that are essential for cancer cell survival, proliferation, and targeted drug resistance in vitro and in vivo [21–24].”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [21]
Citations
Cites
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Dose translation from animal to human studies revisited.
Reagan‐Shaw, S., Nihal, M., & Ahmad, N. (2008) · The FASEB Journal · doi:10.1096/fj.07-9574lsf · Cited by 6,524 · cited 1×
“Using the body surface area (BSA) scaling method (22) recommended by the U.”
MethodImproved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239 · cited 1×
“We performed a genome-wide CRISPR-Cas9 screen (27) for essential genes in our ATRX null model system, using the GeCKOv2 sgRNA library (28), which contains 123,411 sgRNAs targeting 19,050 genes and 1,864 miRNAs.”
MethodGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234 · cited 1×
“We performed a genome-wide CRISPR-Cas9 screen (27) for essential genes in our ATRX null model system, using the GeCKOv2 sgRNA library (28), which contains 123,411 sgRNAs targeting 19,050 genes and 1,864 miRNAs.”
MethodClonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188 · cited 1×
“Clonogenic survival assay The clonogenic survival assay was performed according to the protocol as described previously (17).”
MethodSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890 · cited 1×
“Such screens have been used to identify potential pharmacologic targets that enable selective killing of cancer cells with deficiencies in tumor suppressors TP53 or ARID1A (9, 10), or even with activation of “undruggable” oncogenes including RAS or MYC (11, 12).”
BackgroundLi, W., Xu, H., Xiao, T., Cong, L., Love, M. I., Zhang, F., Irizarry, R. A., Liu, J. S., Brown, M., & Liu, X. S. (2014) · Genome Biology · doi:10.1186/s13059-014-0554-4 · Cited by 2,684 · cited 1×
“The raw sgRNA count file was uploaded to the Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK) algorithm to generate a maximum-likelihood estimation (mle) of gene essentiality score (b score) for each gene using the MAGeCK mle module (15).”
MethodSelf-citationDriver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
Schwartzentruber, J., Korshunov, A., Liu, X.-Y., Jones, D. T. W., Pfaff, E., Jacob, K., Sturm, D., Fontebasso, A. M., Quang, D.-A. K., Tönjes, M., et al. (2012) · Nature · doi:10.1038/nature10833 · Cited by 2,631
Cited by
Zhang, H., Qin, C., An, C., Zheng, X., Wen, S., Chen, W., Liu, X., Lv, Z., Yang, P., Xu, W., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01431-6 · Cited by 247
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 177
Aguilera, P., & Lopez-Contreras, A. J. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.02.009 · Cited by 124
Corticotroph Aggressive Pituitary Tumors and Carcinomas Frequently Harbor ATRX Mutations
Casar‐Borota, O., Boldt, H. B., Engström, B. E., Andersen, M., Baussart, B., Bengtsson, D., Berinder, K., Ekman, B., Feldt‐Rasmussen, U., Höybye, C., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa749 · Cited by 115
“Inactivation of ATRX or, less frequently, DAXX in ATRX / DAXX mutated tumors, leads to telomere destabilization and facilitates the process of alternative lengthening of telomeres (ALTs), which results in cancer cell immortality (19, 20).”
BackgroundInfluentialTargeted therapy for osteosarcoma: a review
Li, S., Zhang, H., Liu, J., & Shang, G. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-04614-4 · Cited by 112
Self-citation
Metadata
- Authors
- Liang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., Yan, H., Zeng, Y.-X., Wang, X., & Jiao, Y.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Duke University (US)
- Sun Yat-sen University Cancer Center (CN)
- Corresponding author
- Wang, Xiaoyue
- Jiao, Yuchen
- ORCID
- Venue
- Cancer Research
- Published
- 2020-02-01
- Volume
- 80
- Issue
- 3
- Pages
- 510-523
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2976399137
- Cited by
- 75
- References
- 49
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 10 · 2023: 13 · 2022: 16 · 2021: 11 · 2020: 10
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation Fund (81472559, 81502420)
- National Key Basic Research Program of China (2015CB553902)
- CAMS (2017-I2M-4-003, 2017-I2M-4-002)
- Infection Diseases of China (2017ZX10201021-007-003)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ATRX mutation, WEE1 inhibition, AZD1775, synthetic lethality, hepatocellular carcinoma, glioma, DNA damage-induced apoptosis, drug target identification, checkpoint kinase
- MeSH terms
- X-linked Nuclear Protein, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Nuclear Proteins, Protein-Tyrosine Kinases, Pyrimidinones, Cell Cycle Proteins, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition. https://app.cochat.ai/papers/10.1158/0008-5472.can-18-3374
- The paper
- Liang, J., Zhao, H., Diplas, B. H., Liu, S., Liu, J., Wang, D., Lu, Y., Zhu, Q., Wu, J., Wang, W., Yan, H., Zeng, Y.-X., Wang, X., & Jiao, Y. (2020). Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX -Mutant Cancers to WEE1 Inhibition. Cancer Research. https://doi.org/10.1158/0008-5472.can-18-3374
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.